Skip To Main Content
Lilly
Menu closed
Lilly
  • Account Login / Register
  • Medical Home
    • Medical Information
  • Medical Education
  • Science
Ask Lilly

We're here to help.

Chat
Chat with us Chat with us
Question Contact Us
Expand contact lilly
Lilly

You are now leaving the Lilly Medical website

The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to Lilly Medical

  1. Medical Information Right
  2. Oncology Right
  3. Inluriyo (imlunestrant) tablets Right
  4. How should Inluriyo™ (imlunestrant) be administered?
Search Inluriyo (type in keywords)
Search Medical Information

If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)

Loading icon

Inluriyo ™ (imlunestrant) tablets

200 mg

Full Prescribing Information

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

How should Inluriyo™ (imlunestrant) be administered?

The recommended dosage of Inluriyo (imlunestrant) is 400 mg taken orally once daily at approximately the same time every day.

US_cFAQ_IML604_DOSING_ADMINISTRATION
US_cFAQ_IML604_DOSING_ADMINISTRATIONen-US

Imlunestrant Dosing and Administration

The recommended dosage of imlunestrant is 400 mg taken orally, once daily, at approximately the same time every day.1

Patients should take imlunestrant on an empty stomach at least 2 hours before food, or 1 hour after food.1

Pre/perimenopausal women and men treated with imlunestrant should receive a gonadotropin-releasing hormone agonist (GnRH) according to current clinical practice standards.1

If a dose of imlunestrant is missed by 6 or more hours or vomiting occurs, skip the dose and take the next dose the following day at the regularly scheduled time.1

Patients should swallow the tablets whole. Do not split, crush, or chew the tablets.1

Continue treatment until disease progression or unacceptable toxicity.1

Enclosed Prescribing Information

INLURIYO™ (imlunestrant) tablets, for oral use, Lilly

Reference

1Inluriyo [package insert]. Indianapolis, IN: Eli Lilly and Company; 2025.

Date of Last Review: June 05, 2025

Are you satisfied with this content?

Can't find what you're looking for? Contact us for answers to your medical questions.

  • Copyright
  • Terms of Use
  • Privacy Statement
  • Consumer Health Privacy Notice
  • Accessibility Statement
  • Sitemap

    This site is intended for US Healthcare Professionals only.

    4.0.47 9/2025 | GLOOTH00001 04/2015 | © Lilly USA, LLC 2025. All rights reserved.

    Product names listed above are trademarks or registered trademarks owned by or licensed to Eli Lilly and Company, its subsidiaries, or affiliates

    California Consumer Privacy Act (CCPA) Opt-Out Icon Your Privacy Choices
    Cookie Settings
    facebook twitter linkedin
    visit www.phactmi.org
    Lilly